U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H47O6.Na
Molecular Weight 538.691
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FUSIDATE SODIUM

SMILES

[Na+].[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C([O-])=O

InChI

InChIKey=HJHVQCXHVMGZNC-JCJNLNMISA-M
InChI=1S/C31H48O6.Na/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);/q;+1/p-1/b26-20-;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;/m0./s1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C31H47O6
Molecular Weight 515.7013
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.

CNS Activity

CNS Penetrant
2554
Curator's Comment: CNS penetration is low.

Originator

Approval Year

2013
596
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 1.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
FUCIDIN

Approved Use

For use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns.
Curative
Approved
8429
FUCICORT

Approved Use

FUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus
PubMed

PubMed

TitleDatePubMed
Haematuria during methicillin therapy.
1971 Jul
Staphylococcal septicaemia complicated by probable cloxacillin neurotoxicity and by jaundice induced by fusidic acid.
1983 Apr
Screening for new compounds with antiherpes activity.
1984 Oct
Susceptibility of mycobacteria to fusidic acid.
1990 Apr
Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.
1990 Sep
Acute renal failure following intravenous fusidic acid.
1993
Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages.
1994 May-Jun
Acute renal failure in association with fusidic acid.
1997 Jun
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
1997 May
Hypocalcaemia during fusidic acid therapy.
2002 Feb
[Cholestatic icterus induced by the administration of fusidic acid in a cirrhotic patient].
2002 Jun 29
Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.
2006 Aug
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.
2009 Apr
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
2013 Dec
Canine ocular thelaziosis caused by Thelazia callipaeda in Portugal.
2013 Jul
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Patents

Patents

06054711
5
20090131389
4
8933063
4
WO2007051468A2
4

Sample Use Guides

In Vivo Use Guide
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration: Topical
In Vitro Use Guide
In vitro fusidic acid inhibited S. aureus (minimum inhibitory concentration [MIC], 0.25 ug/mL), Micrococcus luteus (MIC, 0.25–0.5 ug/mL), Corynebacterium spp. (MIC, 0.06–0.12 ug/mL), Moraxella catarrhalis (MIC, 0.06–0.12 ug/mL), and Neisseria meningitidis (MIC, 0.12–0.25 ug/mL).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:08 UTC 2023
Edited
by admin
on Fri Dec 15 15:01:08 UTC 2023
Record UNII
J7P3696BCQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FUSIDATE SODIUM
USAN   WHO-DD  
USAN  
Official Name English
Fusidate sodium [WHO-DD]
Common Name English
SQ 16360
Code English
FUCIDIN LEO
Brand Name English
FUCIDINE
Brand Name English
SODIUM FUSIDATE [EP MONOGRAPH]
Common Name English
SODIUM FUSIDATE [JAN]
Common Name English
FUSIDATE SODIUM [USAN]
Common Name English
SODIUM FUSIDATE
EP   MART.  
Common Name English
FUSIDIC ACID, SODIUM SALT
Common Name English
29-NORDAMMARA-17(20),24-DIEN-21-OIC ACID, 16-(ACETYLOXY)-3,11-DIHYDROXY-, MONOSODIUM SALT, (3.ALPHA.,4.ALPHA.,8.ALPHA.,9.BETA.,11.ALPHA.,13.ALPHA.,14.BETA.,16.BETA.,17Z)-
Common Name English
ZN-6
Code English
SODIUM FUSIDATE [MART.]
Common Name English
Sodium 3α,11α,16β-trihydroxy-29-nor-8α,9β,13α,14β-dammara-17(20),24-dien-21-oate 16-acetate
Common Name English
SQ-16360
Code English
FUCIDIN
Brand Name English
FUSIDIC ACID SODIUM SALT [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28394
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
FDA ORPHAN DRUG 723519
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
FDA ORPHAN DRUG 400513
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
NCI_THESAURUS C52588
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
Code System Code Type Description
PUBCHEM
23672955
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
EVMPD
SUB12288MIG
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
SMS_ID
100000079317
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
212-030-3
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
MERCK INDEX
m5616
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY Merck Index
FDA UNII
J7P3696BCQ
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID9045552
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
DAILYMED
J7P3696BCQ
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
RXCUI
9874
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY RxNorm
CAS
751-94-0
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL383466
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
DRUG BANK
DBSALT000340
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
NCI_THESAURUS
C65792
Created by admin on Fri Dec 15 15:01:08 UTC 2023 , Edited by admin on Fri Dec 15 15:01:08 UTC 2023
PRIMARY
Related Record Type Details
Structure of FUSIDIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FUSIDIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966